Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration

NCT00090623 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00090623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00090623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2004
Completion date
March 31, 2007
Enrollment
180
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration